Table 2.

The development of β-and γ-secretase inhibitors.

Compounds	Chemical class	Assignee	Patent number	Phases	Ref.
β-secretase inhibitors
LY2886721	Aminothiazine derivatives	Eli Lilly and Co., USA	WO005738A1(2011)	Phase I/II	[44]
LY2811376	Aminodihydrothiazine derivatives	Eli Lilly and Co., USA	WO134617A1(2009)	Phase I	[45]
MK-8931	Imidazole derivatives	Schering Corp., USA	US0287692A1(2007)	Phase II/III	[46]
2a	Lactams derivatives	Pfizer, Inc., USA	WO172449A1(2012)	Discovery	[41]
3a	Thioamidine derivatives	Pfizer, Inc., USA	WO030713A1(2013)	Discovery	[42]
4a	Tricyclicderivatives	Array Biopharma Inc., USA; Genentech, Inc., USA	WO148851A1(2013)	Discovery	[43]
γ-secretase inhibitors
LY-450139	Butanamides	Eli Lilly and Co., USA	US0299053A1(2007)	Phase III	[47]
BMS-708163	Trifluoropentanamides	Bristol-Myers Squibb Co., USA	US0260837A1(2010)	Phase II	[48]
NIC5-15	Pinitol	Waratah Pharmaceuticals, Inc., USA	US0105631A1(2010)	Phase II	[49]
GSI-953	Thiophene sulfonamide	Wyeth, USA	US0181932A1(2009)	Phase I	[50]
PF-3084014	Pentanamide derivatives	Pfizer, Inc., USA	US0215610A1(2005)	Phase I	[51]
BMS299897	Sulfonamide	Elan Pharmaceuticals, Inc., USA	US0045499A1(2008)	Discovery	[52]
CHF5074	Flurbiprofen derivatives	Chiesi Pharmaceuticals, Inc., USA	WO015287A2(2011)	Phase II	[53]
E2012	2-piperidinone derivatives	Schering Corp., USA	US20110027264A1	Preclinical	[54]
5a	Bicyclic pyridinones	Pfizer, Inc., USA	WO2012131539 A1	Discovery	[55]
6a	Tetrasubstituted benzenes	Envivo Pharmaceuticals, Inc., USA	US20130165486 A1	Discovery	[56]